Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants With Advanced/Metastatic Gastrointestinal Tumors

NCT07263594 is registered in ClinicalTrials.gov with DualityBio Inc. as lead sponsor.

NCT NCT07263594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07263594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants With Advanced/Metastatic Gastrointestinal Tumors
Lead sponsor
DualityBio Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 20, 2026
Completion date
December 31, 2028
Enrollment
127 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal cancer